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ABSTRACT: The emergence of plasmid borne colistin resistance in recent years has been problematic as a result of 
the potential for rapid dissemination through bacterial populations. This mcr-1 mediated resistance has been reported 
from around the globe and active surveillance is essential to monitor the developing issue. This study set out to 
determine the occurrence of such strains in a group of 60 Escherichia coli isolates using DNA extraction and 
amplification techniques. Following molecular confirmation of the identities of the E. coli isolates based on the 
detection of E. coli specific 16sRNA gene fragments, phenotypic colistin resistance of isolates was determined and 
isolates were screened for the mcr-1 gene using standard procedures. Of the 35 confirmed E. coli isolates, 60% were 
found to be colistin resistant, with a higher level of resistance noted among the non-clinical isolates. Plasmid mediated 
mcr-1 resistance was however found to be present in only 8.6% of total isolates, making up 14.3% of the colistin 
resistant strains. This mcr-1 mediated resistance was only noted in clinical isolates however. This detection of mcr-1 
mediated colistin resistance in E. coli isolates from Port Harcourt, Nigeria is worrisome as it could point at a looming 
epidemic of colistin resistance and hence the development of untreatable bacterial isolates. Further studies are essential 
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Colistin, a member of the polymyxin family of 
antibiotics has in recent years been described by the 
World Health Organization as a human medicine of 
critical importance (WHO 2011). This antibiotic is 
currently considered a drug of last resort, used in the 
treatment of multidrug resistant Enterobacteriaceae. 
Over the years the introduction of new antibiotics has 
led to the subsequent and nearly immediate 
development of resistant isolates. This phenomenon 
has led to the current situation of a multidrug 
resistant global epidemic leading to the declaration of 
a state of emergency. One of the latest of such 
resistance which has increasingly been recognized, is 
the carbapenem resistance in Enterobacteriaceae 
described as carbapenem resistant Enterobacteriaceae 
(CRE). 
 
First described in the late 2000s (Schwaber and 
Carmeli 2008), these resistant isolates are a further 
evolution of the notorious extended spectrum beta 
lactamases (ESBLs) producing bacteria. CRE 
resistance is as a result of the production of the 
carbapenemases enzymes which confer broad 
resistance to both carbapenems and most of the beta 
lactam antibiotics (Codjoe and Donkor 2018). Prior 
to the emergence of carbapenem resistance, 
carbapenem was considered a drug of last resort for 
ESBL producing bacteria, this role was therefore 
subsequently taken over by colistin. Similar to the 
trend over the years, the reintroduction of colistin 
into clinical practice led to the detection of colistin 
resistant bacteria in several key bacteria of clinical 
importance (Lim et al., 2010).Subsequently, 
detection of colistin resistance has since been made, 
with resistance of up to 25% reported and a general 
worldwide prevalence of about 10%. Some studies 
however also went on to report an association 
between this resistance and specific regions (Giske 
2015, Al-Tawfiqet al., 2017). 
 
Prior to 2016, colistin resistance was generally 
chromosomal mediated and hence associated with 
vertical transmission and a slow rate of evolution. 
This resistance was thought to involve the 
modification of bacterial lipopolysaccharide due to 
an upregulation of PhoP-PhoQ, as well as changes in 
the mcrB gene.  
 
The colistin resistance story changed in 2016 with the 
first documentation of plasmid-mediated colistin 
resistance (Liu et al., 2016). This was first described 
in China from Escherichia coli isolated from animals 
Molecular Detection of Mobilized Colistin Resistance…..                                                                                 402 
OTOKUNEFOR, K; TAMUNOKURO, E; AMADI, A 
 
mediated by the mcr-1 gene which encodes an 
enzyme belonging to the phospohethanolamine 
transferase family. Plasmid encoded colistin 
resistance is worrisome as it opens the possibility of 
horizontal gene transfer and hence a more rapid 
spread of this resistance through bacterial 
populations. 
 
Though the initial report of this plasmid resistance 
noted a high association with animals, a SENTRY 
antimicrobial surveillance program published in 2016 
which screened 390 clinical E. coli and Klebsiella 
pneumonia isolates previously noted as having MICs 
of ≥4µg/ml of colistin and 314 CRE, found 19 
positive for mcr-1.  
 
All positive isolates were E. coli, and had been 
obtained from 10 different countries (Castanheira et 
al., 2016). A 2017 reported noted thatmcr-1 plasmid 
mediated colistin resistance has been detected in over 
36 countries, three of which were African countries, 
with a single study from Nigeria (Al-Tawfiq et al., 
2017, Olaitan et al., 2016).As this is a developing 
situation, surveillance is crucial to monitor the rate of 
development and dissemination of this resistance. 
This study therefore set out to assess a group of E. 
coli isolates for the presence of the mcr-1 gene. 
 
MATERIALS AND METHODS 
Bacterial Isolates: A total of sixty E. coli isolates 
were used in this study (30 clinical isolates, 30 non-
clinical), the identities of which were determined 
using standard biochemical tests (Cheesbrough 2000, 
Cowan and Steel 1985).  
 
DNA Extraction: Bacterial DNA extraction was 
carried out using the standard boiling method 
(Oliveira et al., 2014). This involved boiling of pure 
bacterial colonies in 100µL of molecular grade water 
for 5 min, followed by centrifugation (10,000g for 
5min) which leaves bacterial DNA suspended in the 
supernatant. 
 
Molecular confirmation of E. coli identity: Molecular 
confirmation of isolates as E. coli was based on the 
detection of E. coli specific 16s rRNA gene fragment 
using the Ec16 primer pair F 5′-
GACCTCGGTTTAGTTCACAGA-3′ and R 5’-
CACACGCTGACGCTGACCA-3′and standard 
amplification protocols as previously described 
(Islam et al., 2016). 
 
Screening for mcr-1 gene: Screening for mcr-1 gene 
was carried out as previously described (Liu et al., 
2016) and simply involved the detection of the mcr-1 
gene fragment using the CLR primer pair: F 5′-
GACCTCGGTTTAGTTCACAGA-3’ and R 5’-
CACACGCTGACGCTGACCA-3’ and standard 
amplification protocols. 
 
Antimicrobial susceptibility testing and screening for 
colistin resistance: Antimicrobial susceptibility 
testing was then carried out using the standard Kirby 
Bauer technique (Bauer 1966, NCCLS 2000). The 
commercial disc used contained ceftazidime, 
cefixime, ofloxacin, augmentin, nitrofurantoin, 
ciprofloxacin, cefuroxime and gentamicinantibiotics. 
Screening for colistin resistance was determined by 
analyzing the ability of isolates to grow at colistin 
concentrations of 2µg/ml in line with the EUCAST 
standard, which describes colistin resistant bacteria as 
isolates exhibiting a ≥ 2µg/ml MIC (Eucast 2016, 
Newton-Foot et al., 2017). 
 
RESULTS AND DISCUSSION 
Following molecular confirmation, only 35 of the 
isolates were confirmed to be E. coli based on the 
presence of the E. coli specific 16s rRNA gene 
fragment, with a higher percentage of this comprised 
of the non-clinical isolates (Table 1). 
 
Screening for colistin resistance: The general screen 
for colistin resistance found 60% of confirmed E. coli 
isolates to be colistin resistant. A higher percentage 
of this resistance was however found represented 
among the non-clinical isolates (Table 2). 
 
Screening for mcr-1 colistin resistance: From the 35 
confirmed E. coli isolates, the mcr-1 gene was found 
to be present in 8.6% of isolates. These isolates made 
up 14.3% of the total colistin resistance though 
colistin resistance mediated by the mcr-1 gene was 
found to occur only in the clinical isolates U3, U7 
and U12. 
 
Characteristics of mcr-1 mediated colistin resistant 
isolates: These mcr-1 mediated colistin resistant 
isolates were found to exhibit a similar range of 
susceptibilities. All of the three isolates were resistant 
to Augmentin, Ceftazidime and Cefuroxime, but 
susceptible to gentamicin, ofloxacin, nitrofurantoin 
and ciprofloxacin. U7 and U12 were additionally 
resistant to Cefixime. 
 
The recent detection of the mcr-1plasmid mediated 
colistin resistance opened up the possibility of a new 
threat to the current war against drug resistance 
development. Though initially detected in animal 
strains of E. coli, mcr-1 has since been reported in 
various clinical strains from around the globe and 
surveillance is crucial to monitoring the developing 
situation. 
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Table 1: Genotypic and Phenotypic Correlation of Isolate Identity 
 Clinical Non-Clinical 
Molecular Confirmation of E coli 13 (43.3%) 22 (73.3%) 
 
 
Table 2: Distribution of colistin resistance among isolates 
 Clinical (n = 13) Non-Clinical (n = 22) Total (n = 35) 
Colistin resistant isolates 6 (46.2%) 15 (68.2%) 21 (60%) 
 
Prior to the detection of the mcr-1 plasmid borne 
colistin resistance, colistin resistance had been 
generally described. In this present study, a general 
colistin resistance rate of 60% was noted. This was 
much higher than reports which described resistance 
rates ranging from 0.47% to14.3%, (Kluytmans-van 
den Bergh et al., 2016, Luo et al., 2017, Rossi et al., 
2017, Chan et al., 2018, Del-Bianco et al., 2018, 
Yoon et al., 2018). The colistin resistance rate 
detected in this study was even still higher than 
studies which reported ‘high rates’ of colistin 
resistance (Nachimuthu et al., 2016, Huang et al., 
2017, Alba et al., 2018). These studies had reported 
rates ranging from 24.3% to 28.7%.Some of these 
studies describing high rates of colistin resistance had 
noted them in non-clinical isolates. These higher 
rates have been thought to result from a use of 
colistin in farming as a growth hormone whereby the 
drug is used in low concentrations to alter the flora of 
the animals leading to improved nutrient uptake (Al-
Tawfiq et al., 2017). This study similarly noted a 
higher rate of colistin resistance in the non-clinical 
isolates as opposed to the clinical isolates. 
 






Following the initial report of mcr-1 plasmid 
mediated colistin resistance; active surveillance has 
taken place to properly understand the scope of the 
problem. Overall prevalence rates ranging from 
0.14% to 2.08% have been widely reported, with 
majority of reports showing a less than 1% 
prevalence rate (Luo et al., 2017, Saavedra et al., 
2017, Cao et al., 2018, Chan et al., 2018, Del-Bianco 
et al., 2018). These rates are much lower than the 
8.3% overall prevalence reported in this study. The 
single outlier study reporting a prevalence value out 
of this range (4.7%) was a report from Thailand 
(Eiamphungporn et al., 2018). Focusing specifically 
on the rate of colistin resistance linked with mcr-1, 
studies went on to report rates ranging from 2.3% to 
52.5%. These studies differed in their source of 
isolates, geographical location and time frame 
covered. One study which reported an 83% rate of 
colistin resistance linked with mcr-1 made these 
findings in non-clinical isolates rather than clinical 
isolates (Newton-Foot et al., 2017). The relatively 
low rate of16.8% detected in this study might perhaps 
point at a lack of dissemination of this gene in this 
locale. Alternatively, the relatively low rate might be  
 
An indication of the lack of extensive sampling 
carried out. The limited number of isolates analyzed 
is a major limitation of this study. The results of this 
study could therefore serve as preliminary data which 
would require more extensive, possibly hospital wide 
studies to confirm 
 
Conclusion: This study provides one of the first 
reports of the detection of three cases of mcr-1 
plasmid mediated colistin resistance in Port Harcourt, 
Nigeria. The detection of such strains is worrisome 
considering the potential negative effect the spread of 
this gene has in the fight against drug resistance. 
More systematic studies would however need to be 
carried out to have a proper assessment of the spread 
and scope of the situation. 
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